Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
WXXWY WUXI BIOLGCS ADR
16.270
+0.205+1.28%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(FY)2020/12/31(FY)2019/12/31(FY)2018/12/31
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
Net income from continuing operations
103.13% 3.99B 74.48% 1.97B 52.72% 1.13B 142.92% 737.72M
Other non cash items
39.79% -45.13M -18.45% -74.95M 20.04% -63.27M -408.52% -79.13M
Change In working capital
-162.44% -963.33M -69.89% -367.06M 12.07% -216.07M -64.42% -245.74M
-Change in receivables
-42.74% -1.99B -159.06% -1.39B -12.62% -537.96M -135.21% -477.66M
-Change in inventory
-11.17% -783.19M -649.45% -704.52M 1.75% -94.01M 31.12% -95.68M
-Change in prepaid assets
13.12% -3.41M -222.17% -3.92M 87.52% -1.22M 14.26% -9.76M
-Change in other current assets
8.39% 1.07B 707.90% 987.85M -205.62% -162.5M -- 153.85M
Cash from discontinued investing activities
Operating cash flow
82.39% 3.43B 55.72% 1.88B 58.62% 1.21B 111.39% 761.61M
Investing cash flow
Cash flow from continuing investing activities
Net PPE purchase and sale
-8.12% -6.44B -87.03% -5.96B -137.74% -3.19B -99.84% -1.34B
Net intangibles purchase and sale
-- -- -- 0 99.76% -1.19M -2,760.21% -489.9M
Net business purchase and sale
-1,533.05% -2.54B 48.39% -155.24M -- -300.82M -- --
Net investment purchase and sale
4.27% -1.06B -51.56% -1.1B -156.98% -728M 182.47% 1.28B
Net other investing changes
1,220.80% 313.95M 91.56% -28.01M -686.76% -331.72M 175.47% 56.53M
Cash from discontinued investing activities
Investing cash flow
-33.06% -9.6B -60.58% -7.22B -980.08% -4.49B 81.20% -416.07M
Financing cash flow
Cash flow from continuing financing activities
Net issuance payments of debt
-106.09% -52.98M -54.42% 870.46M -- 1.91B -- 0
Net common stock issuance
50.79% 8.52B 57.07% 5.65B 11.50% 3.6B -9.73% 3.23B
Net other financing activities
-- -- -- 216.89M -- -- 100.72% 600K
Cash from discontinued financing activities
Financing cash flow
25.04% 8.21B 21.30% 6.57B 68.79% 5.41B 43.85% 3.21B
Net cash flow
Beginning cash position
14.35% 7.1B 51.93% 6.21B 710.59% 4.08B 197.97% 503.88M
Current changes in cash
65.69% 2.04B -42.14% 1.23B -40.13% 2.13B 843.93% 3.55B
Effect of exchange rate changes
61.37% -131.5M -5,697.96% -340.4M -120.85% -5.87M 167.76% 28.16M
End cash Position
26.88% 9B 14.35% 7.1B 51.93% 6.21B 710.59% 4.08B
Free cash flow
25.38% -3.09B -104.46% -4.14B -89.60% -2.03B -226.43% -1.07B
Currency Unit
CNYCNYCNYCNY

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
CEO: Dr. Chen Zhisheng
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist